

KURZPROTOKOLL **CA20977T**

Öffentlicher Titel	Phase III Studie zu Nivolumab neoadjuvant und adjuvant bei nicht-kleinzelligem Lungenkrebs
Wissenschaftl. Titel	A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy plus Nivolumab versus Neoadjuvant Chemotherapy plus Placebo, followed by Surgical Resection and Adjuvant Treatment with Nivolumab or Placebo for Participants with Resectable Stage II-IIIB Non-small Cell Lung Cancer
Kurztitel	CA20977T
Studienart	multizentrisch, prospektiv, Therapiestudie, randomisiert, Pharma-Studie, doppelblind, zweiarmig
Studienphase	Phase III
Erkrankung	Lunge: Lungenkrebs: Nicht kleinzelliges Lungenkarzinom (NSCLC) - neoadjuvant
Einschlusskriterien	<ul style="list-style-type: none">- Participants with suspected or histologically confirmed Stage IIA (> 4 cm) to IIIB (T3N2) non-small cell lung carcinoma (NSCLC) with disease that is considered resectable- No brain metastasis- Treatment-naive for NSCLC (no prior systemic anti-cancer treatment)- Eastern Cooperative Oncology Group (ECOG) Performance Status of <= 1- Ability to provide surgical or biopsy tumor tissue for biomarkers
Ausschlusskriterien	<ul style="list-style-type: none">- Participants with an active, known or suspected autoimmune disease are excluded- Any positive test for hepatitis B virus or hepatitis C virus or human immunodeficiency virus (HIV) indicating acute or chronic infection- Any previous anti-cancer treatment including cytotoxic, IO treatment, targeted agents, or radiotherapy
Alter	18 - 99 Jahre
Sponsor	Bristol-Myers Squibb
Registrierung in anderen Studienregistern	ClinicalTrials.gov NCT04025879 EudraCT 2019-000262-38